Helaina’s US$45M funding paves way for new nutritional products with “human-equivalent proteins”

26 Sep 2024 — Helaina, a biotechnology firm innovating nutrition with human-equivalent bioactive proteins, reveals it has received US$45 million in a Series B funding round, which increases its total equity funding to US$83 million. Avidity Partners led the round, with additional contributions from Spark Capital, Ingeborg Investments, Tom Williams of Heron Rock, Barrel Ventures, Siam Capital, Relish Works, CF Private Equity and Primary Venture Partners, among others.